A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
NCT ID: NCT05175352
Last Updated: 2024-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
16 participants
INTERVENTIONAL
2022-06-07
2024-10-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Administration of Cendakimab and Cytochrome P450 (CYP) substrates
Cendakimab
Specified dose on specified days
CYP substrates
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cendakimab
Specified dose on specified days
CYP substrates
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Previously received an adequate trial of proton-pump inhibitor medication that did not provide complete response to EoE
* EoE symptoms documented in daily diary during the screening period
Exclusion Criteria
* Demonstrates evidence of immunosuppression or is receiving systemic immunosuppressive or immunomodulating drugs
* Currently receiving a high potency topical corticosteroid for dermatologic use
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 004
Tucson, Arizona, United States
Local Institution - 001
Los Angeles, California, United States
Local Institution - 022
San Diego, California, United States
Local Institution - 016
Bristol, Connecticut, United States
Local Institution - 002
Inverness, Florida, United States
Local Institution - 010
Miami, Florida, United States
Local Institution - 021
Plantation, Florida, United States
Local Institution - 020
Gurnee, Illinois, United States
Local Institution - 008
Iowa City, Iowa, United States
Local Institution - 003
Albuquerque, New Mexico, United States
Local Institution - 018
Durham, North Carolina, United States
Local Institution - 012
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CC-93538-DDI-001
Identifier Type: -
Identifier Source: org_study_id